 "AstraZeneca gains 5% on marketing nod to launch cancer drug in India")
AstraZeneca Pharma India was up 5% to Rs 1,416 on the BSE in early morning trade after the company said it has received approval from the Drug Controller General of India to market Durvalumab, a cancer treatment medicine.
“The company has received import & market permission for Durvalumab (ImfinziTM) in India by the Drug Controller General of India (DCGI). The receipt of this permission paves way for the launch of durvalumab (ImfinziTM) in India, subject to the receipt of further related statutory approvals and licenses,” AstraZeneca Pharma India said in a press release.
Durvalumab provides a treatment option for patient with locally advanced, unresectable non-small cell lung cancer (NSCLC) and metastatic urothelial carcinoma. Durvalumab is a patented product of AstraZeneca global, it added.
The company said Durvalumab is the only immunotherapy approved for patients with unresectable stage III non-small cell lung cancer (NSCLC). The medicine was granted US FDA ‘breakthrough therapy’ designation on July 31, 2017.
Shares of AstraZeneca Pharma hit a 52-week high of Rs 1,515 on June 19, 2018 in intra-day trade, has rallied 21% in past two weeks. On comparison, the S&P BSE Sensex was down 0.12% during the period.
At 09:45 am; the stock was trading 3% higher at Rs 1,392 as compared to 0.22% decline in the benchmark index. A combined 133,393 shares changed hands on the BSE and NSE.
“The company has received import & market permission for Durvalumab (ImfinziTM) in India by the Drug Controller General of India (DCGI). The receipt of this permission paves way for the launch of durvalumab (ImfinziTM) in India, subject to the receipt of further related statutory approvals and licenses,” AstraZeneca Pharma India said in a press release.
Durvalumab provides a treatment option for patient with locally advanced, unresectable non-small cell lung cancer (NSCLC) and metastatic urothelial carcinoma. Durvalumab is a patented product of AstraZeneca global, it added.
The company said Durvalumab is the only immunotherapy approved for patients with unresectable stage III non-small cell lung cancer (NSCLC). The medicine was granted US FDA ‘breakthrough therapy’ designation on July 31, 2017.
Shares of AstraZeneca Pharma hit a 52-week high of Rs 1,515 on June 19, 2018 in intra-day trade, has rallied 21% in past two weeks. On comparison, the S&P BSE Sensex was down 0.12% during the period.
At 09:45 am; the stock was trading 3% higher at Rs 1,392 as compared to 0.22% decline in the benchmark index. A combined 133,393 shares changed hands on the BSE and NSE.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%